LynneAiBuiMD

Breast Cancer, Gastrointestinal Cancer, Hematologic Oncology

Founder & Chairman, Global Cancer Research Institute, Inc. Founder and Chairman GCRI Foundation, Inc. Ajdunct Clinical Professor Stanford Hospital & Clinics Co-Founder, President, and CEO Annam Pharma, Inc. President/CEO LBS Associates, LLC

Join to view full profile

Dr. Bui is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Bui's full profile

Already have an account?

Office
2242 Camden Ave
San Jose, CA 95124
Phone+1 800-220-0182

Fax+1 408-847-6196
Is this information wrong?

Education & Training

UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 2000 - 2003
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 1997 - 2000
David Geffen School of Medicine at UCLAClass of 1997

Certifications & Licensure

CA State Medical License 1998 - 2024

Clinical Trials

Study of XL999 in Patients With Previously Treated Ovarian Cancer Start of enrollment: 2006 Jan 01
Terminated
Phase 2
Study of XL999 in Patients With Metastatic Colorectal Cancer Start of enrollment: 2005 Dec 01
Terminated
Phase 2
Study of XL999 in Patients With Metastatic Renal Cell Carcinoma Start of enrollment: 2005 Dec 01
Terminated
Phase 2
Study of XL999 in Patients With Multiple Myeloma Start of enrollment: 2006 Feb 01
Terminated
Phase 2
Study of XL999 in Patients With Acute Myeloid Leukemia (AML) Start of enrollment: 2006 May 01
Terminated
Phase 2
Safety Study of XL999 in Adults With Non-Small-Cell Lung Cancer Start of enrollment: 2007 Aug 01
Terminated
Phase 1
Ph1b Study of Oraxol in Comb. w. Ramucirumab in Patients w. Gastric, Gastro-esophageal, or Esophageal Cancers Start of enrollment: 2016 Dec 08
Active, not recruiting
Phase 1
Join now to see all

Publications & Presentations

PubMed

1 citations
The preclinical development of biosimilars: introduction.
Lynne A. Bui> ;Drug Discovery Today. 2015 May 1
41 citations
Key considerations in the preclinical development of biosimilars.
Lynne A. Bui, Susan Hurst, Gregory L. Finch, Beverly Ingram, Ira Jacobs, Carol F. Kirchhoff, Chee-Keng Ng, Anne M. Ryan> ;Drug Discovery Today. 2015 May 1
35 citations
Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor.
Srdan Verstovsek, Constantine S. Tam, Martha Wadleigh, Lubomir Sokol, Catherine C. Smith, Lynne A. Bui, Chunyan Song, Douglas O. Clary, Patrycja Olszynski, Jorge E. Co...> ;Leukemia Research. 2014 Mar 1
20 citations
Developing Clinical Trials for Biosimilars
Lynne A. Bui, Carrie T. Taylor> ;Seminars in Oncology. 2014 Feb 1
2 citations
GABAergic organization of the auditory cortex in the mustached bat (Pteronotus p. parnellii).
Jeffery A. Winer, Lynne A. Bui, Jane H. Hong, Jorge J. Prieto, David T. Larue> ;Hearing Research. 2011 Apr 1
Join now to see all